Plasmodium vivax Polymorphism in a Clinical Drug Trial
AUTOR(ES)
Adak, T.
FONTE
American Society for Microbiology
RESUMO
Data from a double-blind randomized clinical drug trial were analyzed to find the comparative responses of two antirelapse drugs, bulaquine and primaquine, against different relapsing forms of Plasmodium vivax infection. A 1-year follow-up study strongly suggests that the duration of preerythrocytic development of P. vivax is a polymorphic characteristic, exhibited by two strains of hypnozoites responsible for early and late manifestations after primary infection. Short-term relapses were significantly higher in the first half year than long-term relapses, and the reverse was true in the second half year. Clinical drug response data showed that the hypnozoites characterized for short-term relapse were not susceptible to either of the antirelapse drugs in the currently administered dose, whereas hypnozoites characterized for long incubation were significantly susceptible.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=96166Documentos Relacionados
- Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections
- Demonstration of antigenic polymorphism in Plasmodium vivax malaria with a panel of 30 monoclonal antibodies.
- Polymorphism in the Plasmodium vivax msp 3: gene in field samples from Tierralta, Colombia
- Clinical and laboratory findings of Plasmodium vivax malaria in Colombia, 2001
- Does biased gene conversion influence polymorphism in the circumsporozoite protein-encoding gene of Plasmodium vivax?
